THE World Health Organisation (WHO) approved today vaccine of the American company Novavax against coronavirus, which is based on a more classic, different technology from the vaccines widely used in the European Union.
THE The European Medicines Agency (EMA) already approved the release of the vaccine yesterday, Monday aυτTheύ, which is called Nuvaxovid.
In a relevant announcement, the international organization stated that this is tenth vaccine against Covid-19 for which an emergency license is issued, transmits the RES EIA.
Added to Covid vaccines, Covaxin of the Indian Bharat Biontech, Covovax produced by the Serum Institute of India with permission from the American Novovax, Pfizer–Biontech, Modern, AstraZeneca (WHO calculates two AZ vaccines, one of which is manufactured in India), Johnson & Johnson, Sinopharm and Sinovac included in the list of vaccines licensed for emergency use.
The WHO clarifies how Covovax, approved for emergency use on 17 December, comes from Nuvaxovid. The two vaccines “are made with the help of the same technologies” and “require two doses”, while they have in common that “they are stable at refrigerator temperatures between 2 and 8 degrees Celsius”.
In a separate statement, the WHO Vaccine Committee recommends the use of Nuvaxovid for over 18 years and state that doses should be administered “at intervals of three to four weeks».
“The vaccine not “It should be given in less than three weeks,” they said.
WHO approval facilitates international recognition of the vaccine and in particular its use by UN services and the system Covax – created to facilitate access to vaccination for the poorest countries.
Protein-based vaccine
Nuvaxovid is a vaccine with protein based that elicit an immune response, without a virus.
The technology, which is more classic than the vaccines previously approved, is similar to that of the vaccines against hepatitis B and his pertussis, created many decades ago and widely used around the world.
Major clinical trials – one in Britain and the other in the US and Mexico – involving more than 45,000 people showed “approximately 90%»Effectiveness in reducing the incidence of symptomatic Covid.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
